Hideki Katsura

Hideki Katsura

Auto-generated profile, based on publicly available information

Hideki Katsura

Department of Respiratory Medicine Tokyo Women's Medical University Tokyo Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Lung Cancer: Targets and Therapy
Verified
Journal Article
Open access
PDF file
HIHiroshi Isobe
Hiroshi Isobe
KMKiyoshi Mori
Kiyoshi Mori
KMKoichi Minato
Koichi Minato
HKHideki Katsura
Hideki Katsura
KTKazuko Taniguchi
Kazuko Taniguchi
TKTerufumi Kato
Terufumi Kato
Background: Recommended therapies for advanced/metastatic non-small cell lung cancer (NSCLC) have changed with the advent of targeted therapies. The objectives of this retrospective chart review study were to describe treatment patterns, biomarker testing practices, and health care resource use for advanced NSCLC at 5 sites in Japan. Patients and methods: We studied anonymized medical record data of patients aged ≥18 years who initiated systemic therapy for newly diagnosed stage IIIB or IV NSCLC from January 2011 through June 2013. Data were analyzed descriptively by histology and mutation status. Overall survival was estimated using the Kaplan–Meier method. Results: We studied 175 patients, including 43 (25%), 129 (74%), and 3 (2%) with squamous, nonsquamous, and unknown NSCLC histology, respectively; 83% had stage IV NSCLC. Overall, 123 patients (70%) were male; the median age was 70 years (range, 47–86); and 33 (19%) were never-smokers. In the nonsquamous cohort, 105 (81%) and 25 (19%) of patients were tested for epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement, respectively; 44 (42%) had EGFR-positive NSCLC and 2 (8%) had ALK-positive NSCLC, including 26/46 (57%) women and 21/46 (46%) never-smokers. In the squamous cohort, 17 (40%) and 4 (9%), respectively, were tested; 1 EGFR-positive tumor was detected. After first-line therapy, 105 (60%) patients received second-line, and 54/105 (51%; or 31% overall) received third-line therapy. EGFR tyrosine kinase inhibitors were most commonly prescribed for EGFR-positive NSCLC across all lines. In the nonsquamous EGFR/ALK-negative/unknown cohort, most received first-line platinum combinations, particularly younger patients (78% ≥75 years vs 93% <75 years old). The average hospitalization was 21 days/admission. The median (95% CI) overall survival from start of first-line therapy was 9.9 months (7.6–11.7) for all patients and 17.9 months (9.9–24.4) for patients with EGFR/ALK-positive status. Conclusion: Biomarker testing is common for nonsquamous NSCLC at the 5 Japanese study sites. Treatment is personalized by mutation status and age, per guideline recommendations.

12 February 2018 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
MHMizue Hasegawa
Mizue Hasegawa
FSFumikazu Sakai
Fumikazu Sakai
NKNaoko Konda
Naoko Konda
AOAsako Okabayashi
Asako Okabayashi
HKHideki Katsura
Hideki Katsura
YSYohei Seto
Yohei Seto

11 June 2024 in Respirology Case Reports
Verified
Journal Article
Open access
NANaoko Arakawa
Naoko Arakawa
YSYuno Shiota
Yuno Shiota
FOFumi Onizawa
Fumi Onizawa
FMFumi Miyata
Fumi Miyata
AMAzusa Miyoshi
Azusa Miyoshi
ETEtsuko Tagaya
Etsuko Tagaya
A 46‐year‐old male was treated with corticosteroids for nonspecific interstitial pneumonia (NSIP). He was referred to our hospital and admitted for worsening dyspnea and diffuse ground‐glass opacity on chest computed tomography (CT) during corticosteroid treatment. Gottron's sign was observed, and the patient was diagnosed with clinically amyopathic dermatomyositis on skin biopsy. We increased the corticosteroid dose and added immunosuppressive agents; however, the opacity on the chest CT worsened. Based on periodic‐acid‐Schiff‐positive granular material in the bronchoalveolar lavage fluid and the presence of anti‐GM‐CSF antibodies, the patient was diagnosed with autoimmune pulmonary alveolar proteinosis (APAP). The concentration of anti‐GM‐CSF antibodies in preserved serum was also elevated when the patient was diagnosed with NSIP. Thus, we assumed that NSIP and APAP coexisted, and that APAP manifested during immunosuppressive therapy. When exacerbation is observed during the treatment of interstitial pneumonia with immunosuppressive agents, it is necessary to consider APAP.

5 November 2023 in Respiratory Medicine Case Reports
Verified
Journal Article
Open access
YNYoko Nishizawa
Yoko Nishizawa
HKHideki Katsura
Hideki Katsura
YSYuka Sasaki
Yuka Sasaki
RKRyoma Kudo
Ryoma Kudo
AKAki Kizuki
Aki Kizuki
TOTetsuya Ogawa
Tetsuya Ogawa
Mycobacterium abscessus subsp. abscessus (MABA) is refractory and sometimes fatal especially in an immunocompromised patient. Also, MABA-associated pneumothorax is an extremely rare complication. We report a case of MABA pulmonary infection complicated pneumothorax treated successfully. A 69-year-old Japanese female with immunosuppressed systemic sclerosis-associated interstitial lung disease experienced left-sided secondary spontaneous pneumothorax. MABA was detected in the pleural effusion and blood culture. Microbial sensitivity test showed the MABA was sensitive to only amikacin, sitafloxacin, and clofazimine. Combination therapy with these antibiotics including azithromycin achieved remission within three weeks. In the treatment of MABA infection, compliance with microbial sensitivity test is crucial.

30 July 2024 in Respirology Case Reports
Verified
Journal Article
Open access
AMAzusa Miyoshi
Azusa Miyoshi
HKHideki Katsura
Hideki Katsura
TATomohiro Akaba
Tomohiro Akaba
MKMitsuko Kondo
Mitsuko Kondo
ETEtsuko Tagaya
Etsuko Tagaya
Here we report a rare case of immunoglobulin G4 (IgG4)–related pleural disease diagnosed using a thoracoscopic pleural biopsy. A 66‐year‐old man was admitted to our hospital with right‐dominant bilateral pleural effusions and gradually worsening dyspnoea. Chest radiographs revealed right‐dominant pleural effusions, while chest computed tomography showed bilateral pleural effusions without parenchymal lesions. Although the bilateral pleural effusions were exudative with an increased number of lymphocytes, the definitive diagnosis was initially elusive. High IgG4 levels in the serum and pleural effusions were observed. A pathological evaluation of a right pleural biopsy specimen collected via video‐assisted thoracoscopic surgery showed fibrosis‐associated lymphoplasmacytic infiltration, 45–60 IgG4‐positive plasma cells per high‐power field, and an IgG4/immunoglobulin G ratio of 40%. Consequently, the patient was diagnosed with IgG4‐related pleural disease. The bilateral pleural effusions improved after corticosteroid therapy.

9 August 2024 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Open access
KNKoko Nemoto
Koko Nemoto
HHHiromichi Hamada
Hiromichi Hamada
MAMasahiro Anbe
Masahiro Anbe
HKHideki Katsura
Hideki Katsura
KYKeita Yoshida
Keita Yoshida
JTJun-Ichi Takanashi
Jun-Ichi Takanashi